Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AB Science
ClinicalTrials.gov Identifier:
NCT00976118
First received: September 11, 2009
Last updated: May 21, 2013
Last verified: September 2009

September 11, 2009
May 21, 2013
February 2006
July 2008   (final data collection date for primary outcome measure)
change from baseline in ADAS-Cog [ Time Frame: week 24 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00976118 on ClinicalTrials.gov Archive Site
  • change from baseline in ADAS-Cog [ Time Frame: week 4 and 12 ] [ Designated as safety issue: No ]
  • change from baseline in CIBIC-plus [ Time Frame: week 4, 8, 12 and 24 ] [ Designated as safety issue: No ]
  • change from baseline in CDR [ Time Frame: week 12, 24 ] [ Designated as safety issue: No ]
  • change from baseline in MMSE [ Time Frame: week 4, 12 and 24 ] [ Designated as safety issue: No ]
  • change from baseline in NPI [ Time Frame: week 12 and 24 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.

This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010) administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed Alzheimer's type disease.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: masitinib (AB1010)
    oral masitinib 3 or 6 mg/kg/day
    Other Name: AB1010
  • Drug: placebo
    matching placebo to masitinib
  • Placebo Comparator: placebo
    Intervention: Drug: placebo
  • Experimental: oral masitinib (AB1010)
    masitinib (AB1010) 3 or 6 mg/kg/day
    Intervention: Drug: masitinib (AB1010)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
34
February 2009
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Outpatients from both sex
  2. Age ≥ 50 years at screening
  3. Menopause ≥ 2 years for women
  4. Dementia of Alzheimer's type, according to DSM IV criteria
  5. Probable Alzheimer' disease according to NINCDS-ADRDA criteria
  6. MMSE ≥ 12 and ≤ 26 at baseline
  7. CDR of 1 or 2 at baseline
  8. Treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 3 months at baseline, with no changes foreseen in therapy throughout the study
  9. Presence of a reliable caregiver
  10. Patient, identified caregiver and, if applicable, patient surrogate are able and willing to comply with study visits and procedures per protocol, understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed
  11. Affiliated to the French Social Security regimen

Exclusion Criteria:

  1. Any cause of dementia not due to Alzheimer's disease :

    • other central nervous conditions causing progressive deficits in memory and cognition, e.g. cerebrovascular disease, Parkinson's disease, Huntington's disease, brain tumor…
    • systemic conditions known to cause dementia, e.g., hypothyroidism, untreated vitamin B12 or folic acid deficiency, niacin deficiency, neurosyphilis, HIV infection…
    • substance-induced conditions
  2. Alzheimer disease with delusions or delirium
  3. Treatment with any registered or putative cognitive enhancer or disease modifier other than donepezil, galantamine, rivastigmine or memantine
  4. Uncontrolled depression at screening
  5. Evidence of psychosis and/or use of antipsychotic drugs at screening, or history of significant psychotic disorder or hospitalization for psychiatric disorders
  6. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection.
  7. History of infection requiring hospitalization or treatment with antibiotics within 2 weeks of screening
  8. Inadequate organ function, defined as follows : total bilirubin ≥ 1.5 x ULN, SGOT and SGPT ≥ 2.5 x UNL, creatinine clearance calculated by Crocroft method < 35 ml/mn, ANC ≤ 2500, platelets ≤ 100 000 at baseline
  9. Treatment with any investigational agent within 4 weeks of screening,
  10. Men and their partner refusing to use 2 methods of medically acceptable forms of contraception during the study.
  11. History of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
  12. Any condition that, in the investigator's opinion, could be detrimental to subjects participating in this study as life expectancy < 1 year, or any clinically important deviations from normal clinical laboratory values or concurrent medical events.
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00976118
AB04024
No
AB Science
AB Science
Not Provided
Not Provided
AB Science
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP